--- title: Accelerating early-stage CMC development for oral drug products description: Bringing an oral drug candidate into the clinic is not simply a question of moving faster. Success depends on making the right CMC decisions at the right time. In this webinar, we will explore practical strategies to accelerate early-stage CMC development while balancing speed, scientific rigor, and risk. Learn how early CMC involvement, targeted drug substance investments, fit-for-purpose formulation approaches, and smarter development execution can shorten timelines to Phase I and Phase II studies. Discover how informed decision-making and streamlined development strategies can help bring promising therapies to patients faster. image: https://content.siegfried.ch/hubfs/20230424_Siegfried_Barcelona18431_CMYK-1.jpg --- This is a search field with an auto-suggest feature attached. - There are no suggestions because the search field is empty. - [Careers](https://www.siegfried.ch/careers/) - [Media](https://www.siegfried.ch/media/) - [Investors](https://www.siegfried.ch/investors/) - [Contact us](https://www.siegfried.ch/contact/) [Company](https://www.siegfried.ch/company/) Company [Purpose](https://www.siegfried.ch/company/purpose/) [Strategy](https://www.siegfried.ch/company/strategy/) [Leadership](https://www.siegfried.ch/company/leadership/) [History](https://www.siegfried.ch/company/history/) [Locations](https://www.siegfried.ch/company/locations/) [Offering](https://www.siegfried.ch/offering/) Offering [Drug Substances](https://www.siegfried.ch/offering/drug-substances/) [Exclusive synthesis](https://www.siegfried.ch/offering/drug-substances/exclusive-synthesis/) [API portfolio](https://www.siegfried.ch/offering/drug-substances/api/) [Reference standards](https://www.siegfried.ch/reference-standards/) [Preclinical and early-phase development](https://content.siegfried.ch/siegfried-acceleration-hub) [Alkaloid raw materials extraction](https://extractas.com.au/) [Drug Products](https://www.siegfried.ch/offering/drug-products/) [Oral solid dosage forms](https://www.siegfried.ch/offering/drug-products/oral-solids/) [Sterile injectables](https://www.siegfried.ch/offering/drug-products/sterile-injectables/) [Ophthalmics](https://www.siegfried.ch/offering/drug-products/ophthalmics/) [Inhalation products](https://www.siegfried.ch/offering/drug-products/inhalatives/) [Viral vectors](https://dinamiqs.com/) [Technologies](https://www.siegfried.ch/technologies/) [Sustainability](https://www.siegfried.ch/sustainability/) Sustainability [People](https://www.siegfried.ch/sustainability/people/) [Environment](https://www.siegfried.ch/sustainability/environment/environment/) [Integrity](https://www.siegfried.ch/sustainability/integrity/) [Quality](https://www.siegfried.ch/sustainability/quality/) [Community engagement](https://siegfried.ch/sustainability/community-engagement/) [Risk management](https://www.siegfried.ch/sustainability/risk-management/) [Insights](https://content.siegfried.ch/insights) [![](https://content.siegfried.ch/hubfs/siegfried-logo.svg)](https://www.siegfried.ch/) What are you looking for? [![](https://content.siegfried.ch/hubfs/siegfried-logo.svg)](https://www.siegfried.ch/) [Company](https://www.siegfried.ch/company/) [Purpose](https://www.siegfried.ch/company/purpose/) [Strategy](https://www.siegfried.ch/company/strategy/) [Leadership](https://www.siegfried.ch/company/leadership/) [History](https://www.siegfried.ch/company/history/) [Locations](https://www.siegfried.ch/company/locations/) [Offering](https://www.siegfried.ch/offering/) [Drug Substances](https://www.siegfried.ch/offering/drug-substances/) [Exclusive synthesis](https://www.siegfried.ch/offering/drug-substances/exclusive-synthesis/) [API portfolio](https://www.siegfried.ch/offering/drug-substances/api/) [Reference standards](https://www.siegfried.ch/reference-standards/) [Preclinical and early-phase development](https://content.siegfried.ch/siegfried-acceleration-hub) [Alkaloid raw materials extraction](https://extractas.com.au/) [Drug Products](https://www.siegfried.ch/offering/drug-products/) [Oral solid dosage forms](https://www.siegfried.ch/offering/drug-products/oral-solids/) [Sterile injectables](https://www.siegfried.ch/offering/drug-products/sterile-injectables/) [Ophthalmics](https://www.siegfried.ch/offering/drug-products/ophthalmics/) [Inhalation products](https://www.siegfried.ch/offering/drug-products/inhalatives/) [Viral vectors](https://dinamiqs.com/) [Technologies](https://www.siegfried.ch/technologies/) [Sustainability](https://www.siegfried.ch/sustainability/) [People](https://www.siegfried.ch/sustainability/people/) [Environment](https://www.siegfried.ch/sustainability/environment/environment/) [Integrity](https://www.siegfried.ch/sustainability/integrity/) [Quality](https://www.siegfried.ch/sustainability/quality/) [Community engagement](https://siegfried.ch/sustainability/community-engagement/) [Risk management](https://www.siegfried.ch/sustainability/risk-management/) [Insights](https://content.siegfried.ch/insights) - [Careers](https://www.siegfried.ch/careers/) - [Media](https://www.siegfried.ch/media/) - [Investors](https://www.siegfried.ch/investors/) - [Contact us](https://www.siegfried.ch/contact/) Page / Page ![Icon\_Webinar\_V3\_32px](https://content.siegfried.ch/hubfs/Icon_Webinar_V3_32px.svg) On-demand webinar # Accelerating early-stage CMC development for oral drug products Bringing an oral drug candidate into the clinic is not simply a question of moving faster. Success depends on making the right CMC decisions at the right time. In this webinar, we will explore practical strategies to accelerate early-stage CMC development while balancing speed, scientific rigor, and risk. Learn how early CMC involvement, targeted drug substance investments, fit-for-purpose formulation approaches, and smarter development execution can shorten timelines to Phase I and Phase II studies. Discover how informed decision-making and streamlined development strategies can help bring promising therapies to patients faster. Topics Drug Products Oral solid dosage form Dosage Form Early-phase development Regulatory support Access the on-demand webinar recording   About the presenter Markus Weigandt  Markus Weigandt, PhD, is Global Head R&D Drug Products at Siegfried, with over 25 years of experience in the pharmaceutical industry. He has extensive expertise in R&D, CMC development, and GMP manufacturing for both oral and parenteral dosage forms. Prior to joining Siegfried, he spent over two decades at Merck Healthcare KGaA, where he held multiple global and local leadership roles, as Global Head Pharmaceutical Technologies and most recently as Site Head Darmstadt Development & Global Head of Orals Development. Markus holds a Pharmacy degree from Johann Wolfgang Goethe University in Frankfurt and a PhD from Ruprecht Karls University in Heidelberg, Germany.  expect more **Siegfried AG** Untere Brühlstrasse 4 4800 Zofingen, Switzerland [+41 62 746 11 11](tel:+41627461111) [Get in touch](https://www.siegfried.ch/contact-us/) #### About us - [Our company](https://www.siegfried.ch/company/) - [Sustainability](https://www.siegfried.ch/sustainability/) - [Media](https://www.siegfried.ch/media/) - [Investors](https://www.siegfried.ch/investors/) - [Careers](https://www.siegfried.ch/careers/) #### Helpful resources - [Expert insights](https://content.siegfried.ch/insights) - [News archive](https://www.siegfried.ch/news-archive/) - [Reports](https://www.siegfried.ch/investors/investors-download-center-2025/) - [Terms and conditions](https://www.siegfried.ch/terms-and-conditions/) #### Offering - [Drug Substances](https://www.siegfried.ch/offering/drug-substances/) - [Drug Products](https://www.siegfried.ch/offering/drug-products/) - [Technologies](https://www.siegfried.ch/technologies/) 2026 © Siegfried Holding AG - [Privacy Policy](https://www.siegfried.ch/privacy-policy/) - [Legal disclaimer](https://www.siegfried.ch/legal-disclaimer/) - [Imprint](https://www.siegfried.ch/imprint/) ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Markus Weigandt", "url" : "https://content.siegfried.ch/insights/author/markus-weigandt" }, "dateModified" : "2026-09-28T07:53:29.602Z", "datePublished" : "2026-09-28T07:51:29.000Z", "headline" : "Accelerating early-stage CMC development for oral drug products", "image" : [ "https://content.siegfried.ch/hubfs/20230424_Siegfried_Barcelona18431_CMYK-1.jpg" ], "mainEntityOfPage" : { "@id" : "https://content.siegfried.ch/insights/accelerating-early-stage-cmc-development-for-oral-drug-products-1", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://content.siegfried.ch/hubfs/siegfried-logo.svg" } } } ```